Myriad Genetics, Inc. (MYGN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Myriad Genetics, Inc. (MYGN) is down 28.5% since the beginning of the year. At $4 per share, MYGN is trading 48.8% below its 52-week high of $9. Investors who bought $1,000 worth of MYGN shares 5 years ago would now be looking at an investment worth $160.

Myriad Genetics, Inc. (MYGN) has returned -28.46% so far this year and -9.84% over the past 12 months. Over the last ten years, MYGN has returned -18.49% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Oct 6, 1995, MYGN's average daily return is +0.08%, while the average monthly return is +1.57%. At this rate, an investment would double in approximately 3.7 years.

Historically, 50% of months were positive and 50% were negative. The best month was Feb 2000 with a return of +139.5%, while the worst month was Mar 2000 at -61.0%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 9 months.

On a daily basis, MYGN closed higher 49% of trading days. The best single day was Aug 1, 2019 with a return of +54.5%, while the worst single day was Aug 14, 2019 at -42.8%.

Myriad Genetics, Inc. has an annualized alpha of 9.13%, beta of 1.14, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since October 09, 1995.

• This stock participated in 131.60% of S&P 500 Index downside but only 93.36% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MYGN ranks 37 for risk / return — below 37% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Myriad Genetics, Inc. (MYGN) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Myriad Genetics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Myriad Genetics, Inc. was 94.21%, occurring on May 19, 2026. The portfolio has not yet recovered.

The current Myriad Genetics, Inc. drawdown is 92.82%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Myriad Genetics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Myriad Genetics, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.